Clonal selection and therapy resistance in acute leukaemias: Mathematical modelling explains different proliferation patterns at diagnosis and relapse

Journal of the Royal Society Interface

Volumn 11, Issue 94, 2014, Pages

  Stiehl, Thomas ^a   Baran, Natalia ^a   Ho, Anthony D ^a   Marciniak Czochra, Anna ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer stem cells; Clonal evolution; Leukaemia; Mathematical models; Selection process

Indexed keywords

CELL PROLIFERATION; CHEMOTHERAPY; CLONING; CYTOLOGY; HOSPITAL DATA PROCESSING; MATHEMATICAL MODELS; STEM CELLS;

CANCER STEM CELLS; CLONAL EVOLUTION; CLONAL SELECTION; EXPERIMENTAL EVIDENCE; LEUKAEMIA; NEW MATHEMATICAL MODEL; PROLIFERATING CELLS; SELF-RENEWING CELLS;

CLONE CELLS;

ANTINEOPLASTIC AGENT;

ACUTE LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RESISTANCE; CELL CLONING; CELL GROWTH; CELL PROLIFERATION; CELL RENEWAL; CELL SELECTION; CLONAL VARIATION; CONTROLLED STUDY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MATHEMATICAL MODEL; MITOSIS; MOLECULAR DYNAMICS; SIMULATION; ACUTE DISEASE; ANIMAL; ANTIGEN MEDIATED CLONAL SELECTION; BIOLOGICAL MODEL; CANCER STEM CELL; CLONAL EVOLUTION; IMMUNOLOGY; LEUKEMIA; MATHEMATICAL MODELS; METABOLISM; RECURRENT DISEASE; SELECTION PROCESS;

CANCER STEM CELLS; CLONAL EVOLUTION; LEUKAEMIA; MATHEMATICAL MODELS; SELECTION PROCESS;

ACUTE DISEASE; ANIMALS; CELL PROLIFERATION; CLONAL SELECTION, ANTIGEN-MEDIATED; HUMANS; LEUKEMIA; MODELS, BIOLOGICAL; RECURRENCE;

EID: 84896951559     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2014.0079     Document Type: Article

References (86)

1. Ding L et al. 2012 Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510. (doi:10.1038/ nature10738)
2. Bonnet D, Dick JE. 1997 Human acute myeloid leukemia is organised as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737. (doi:10.1038/nm0797-730)
3. Hope KJ, Jin L, Dick JE. 2004 Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738-743. (doi:10.1038/ni1080)
4. Van Delft FW et al. 2011 Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood 117, 6247-6254. (doi:10.1182/blood-2010-10-314674)
5. Choi S et al. 2007 Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood 110, 632-639. (doi:10.1182/blood-2007-01-067785)
6. Lutz C et al. 2013 Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia. Leukemia 27, 1204-1207. (doi:10.1038/leu.2012.306)
7. Jan M, Majeti R. 2013 Clonal evolution of acute leukemia genomes. Oncogene 32, 135-140. (doi:10.1038/onc.2012.48)
8. Parkin B, Ouillette P, Li Y, Keller J, Lam C, Roulston D, Li C, Shedden K, Malek SN. 2013 Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 121, 369-377. (doi:10.1182/blood-2012-04- 427039)
9. Bachas C, Schuurhuis GJ, Assaraf YG, Kwidama ZJ, Kelder A, Wouters F, Snel AN, Kaspers GJ, Cloos J. 2012 The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 26, 1313-1320. (doi:10.1038/leu.2011.383)
10. Sprouffske K, Merlo LM, Gerrish PJ, Maley CC, Sniegowski PD. 2012 Cancer in light of experimental evolution. Curr. Biol. 22, R762-R771. (doi:10.1016/j.cub.2012.06.065)
11. Podlaha O, Riester M, De S, Michor F. 2012 Evolution of the cancer genome. Trends Genet. 28, 155-163. (doi:10.1016/j.tig.2012.01.003)
12. Greaves M, Maley CC. 2012 Clonal evolution in cancer. Nature 481, 306-313. (doi:10.1038/nature10762)
13. Klumper E et al. 1995 In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86, 3861-3868.
14. Ran D et al. 2011 Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance. Exp. Hematol. 40, 155-165. (doi:10.1016/j.exphem.2011.10.005)
15. Anderson K et al. 2011 Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361. (doi:10.1038/nature09650)
16. Lutz C, Hoang VT, Buss E, Ho AD. 2012 Identifying leukemia stem cells - is it feasible and does it matter? Cancer Lett. 338, 10-14. (doi:10.1016/j. canlet.2012.07.014)
17. Mardis ER et al. 2009 Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl. J. Med. 361, 1058-1066. (doi:10.1056/ NEJMoa0903840)
18. Ley TJ et al. 2008 DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 45, 66-72. (doi:10.1038/nature07485)
19. Roeder I. 2006 Quantitative stem-cell biology: computational studies in the hematopoietic system. Curr. Opinion Hematol. 13, 222-228. (doi:10.1097/01.moh.0000231418.08031.48)
20. Foley C, Mackey MC. 2009 Dynamic hematological disease: a review. J. Math. Biol. 58, 285-322. (doi:10.1007/s00285-008-0165-3)
21. Whichard ZL, Sarkar CA, Kimmel M, Corey SJ. 2010 Hematopoiesis and its disorders: a systems biology approach. Blood 115, 2339-2347. (doi:10.1182/blood-2009-08-215798)
22. Manesso E, Teles J, Bryder D, Peterson C. 2013 Dynamical modelling of haematopoiesis: an integrated view over the system in homeostasis and under perturbation. J. R. Soc. Interface 10, 20120817. (doi:10.1098/rsif.2012.0817)
23. Marciniak-Czochra A, Stiehl T, Jäger W, Ho AD, Wagner W. 2009 Modeling of asymmetric cell division in hematopoietic stem cells - regulation of self-renewal is essential for efficient repopulation. Stem Cells Dev. 18, 377-385. (doi:10.1089/scd.2008.0143)
24. Stiehl T, Marciniak-Czochra A. 2011 Characterization of stem cells using mathematical models of multistage cell lineages. Math. Comp. Model. 53, 1505-1517. (doi:10.1016/j.mcm.2010.03.057)
25. Stiehl T, Marciniak-Czochra A. 2012 Mathematical modelling of leukemogenesis and cancer stem cell dynamics. Math. Mod. Natural Phenomena 7, 7166-7202.
26. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T. 2000 Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19, 624-631. (doi:10.1038/sj.onc.1203354)
27. Reilly JT. 2003 FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk. Lymphoma 44, 1-7. (doi:10.1080/1042819021000040233)
28. Polak R, Buitenhuis M. 2012 The PI3 K/PKB module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 119, 911-923. (doi:10.1182/blood-2011-07-366203)
29. Fanin R et al. 1989 Serum lactate dehydrogenase is an important risk determinant in acute lymphocytic leukemia. Haematologica 74, 161-165. (Pubitemid 19134332)
30. Buechner T, Heinecke A. 1996 The role of prognostic factors in acute myeloid leukemia. Leukemia 10(Suppl. 1), S28-S29. (Pubitemid 26146247)
31. Kornberg A, Polliack A. 1980 Serum lactic dehydrogenase (LDH) levels in acute leukemia: marked elevations in lymphoblastic leukemia. Blood 56, 351-355. (Pubitemid 11251011)
32. Welch JS et al. 2012 The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278. (doi:10.1016/j.cell.2012.06.023)
33. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, Majeti R. 2012 Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4, 149ra118.
34. Marciniak-Czochra A, Stiehl T, Wagner W. 2009 Modeling of replicative senescence in hematopoietic development. Aging (Albany NY) 1, 723-732.
35. Nakata Y, Getto P, Marciniak-Czochra A, Alarcon T. 2012 Stability analysis of multi-compartment models for cell production systems. J. Biol. Dyn. 6(Suppl. 1), 2-18. (doi:10.1080/17513758.2011.558214)
36. Getto P, Marciniak-Czochra A, Nakata Y, dM Vivanco M. 2013 Global dynamics of two-compartment models for cell production systems with regulatory mechanisms. Math. Biosci. 245, 258-268. (doi:10.1016/j.mbs.2013.07.006)
37. Jandl JH. 1996 Blood cell formation. In Textbook of hematology (ed. JH Jandl), pp. 1-69. Boston, MA: Littel Brown and Company.
38. Lansdorp PM. 1998 Stem cell biology for the transfusionist. Vox Sang 74(Suppl. 2), 91-94. (doi:10.1111/j.1423-0410.1998.tb05402.x)
39. Rodriguez-Brenes IA, Wodarz D, Komarova NL. 2013 Stem cell control, oscillations, and tissue regeneration in spatial and non-spatial models. Front. Oncol. 3, 82. (doi:10.3389/fonc.2013.00082)
40. Layton JE, Hockman H, Sheridan WP, Morstyn G. 1989 Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74, 1303-1307. (Pubitemid 19227439)
41. Metcalf D. 2008 Hematopoietic cytokines. Blood 111, 485-491. (doi:10.1182/blood-2007-03-079681)
42. Fried W. 2009 Erythropoietin and erythropoiesis. Exp. Hematol. 37, 1007-1015. (doi:10.1016/j.exphem.2009.05.010)
43. Aglietta M et al. 1989 Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J. Clin. Invest. 82, 551-557. (doi:10.1172/JCI113917)
44. Marciniak-Czochra A, Stiehl T. 2011 Mathematical models of hematopoietic reconstitution after stem cell transplantation. In Model based parameter estimation: theory and applications (eds HG Bock, T Carraro, W Jaeger, S Koerkel, R Rannacher, JP Schloederi), pp. 191-206. Heidelberg, Germany: Springer.
45. 4+ cell dose on engraftment after stem cell transplantations: personalised estimates based on mathematical modeling. Bone Marrow Transplant 49, 30-37. (doi:10.1038/bmt.2013.138)
46. Lander A, Gokoffski K, Wan F, Nie Q, Calof A. 2009 Cell lineages and the logic of proliferative control. PLoS Biol. 7, 84-100. (doi:10.1371/journal.pbio. 1000015)
47. Lo W, Chou C, Gokoffski K, Wan F, Lander A, Calof A, Nie Q. 2009 Feedback regulation in multistage cell lineages. Math. Biosci. Eng. 6, 59-82. (doi:10.3934/mbe.2009.6.59)
48. Tsopra OA et al. 2009 Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for necrosis factor-alpha. Acta Haematol. 121, 187-195. (doi:10.1159/000220331)
49. Shinjo K, Takeshita A, Ohnishi K, Ohno R. 1997 Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Leuk. Lymphoma 25, 37-46. (Pubitemid 27165649)
50. Kondo S, Okamura S, Asano Y, Harada M, Niho Y. 1991 Human granulocyte colony-stimulating factor receptors in acute myelogenous leukemia. Eur. J. Haematol. 46, 223-230. (doi:10.1111/j.1600-0609.1991.tb00545.x)
51. Griffin JD, Löwenberg B. 1986 Clonogenic cells in acute myeloblastic leukemia. Blood 68, 1185-1195. (Pubitemid 17228790)
52. Miraki-Moud F et al. 2013 Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc. Natl Acad. Sci. USA 110, 13 576-13 581. (doi:10.1073/pnas.1301891110)
53. Calvi LM et al. 2003 Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846. (doi:10.1038/nature02040)
54. Zhang J et al. 2003 Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841. (doi:10.1038/nature02041)
55. Garrido SM, Appelbaum FR, Willman CL, Banker DE. 2001 Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp. Hematol. 29, 448-457. (doi:10.1016/S0301-472X(01)00612-9)
56. Dommange F et al. 2006 CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J. 20, 1913-1915. (doi:10.1096/fj.05-5667fje)
57. Berger M, Motta C, Boiret N, Aublet-Cuvelier B, Bonhomme J, Travade P. 1994 Membrane fluidity and adherence to extracellular matrix components are related to blast cell count in acute myeloid leukemia. Leuk. Lymphoma 15, 297-302. (doi:10.3109/10428199409049727)
58. Tavor S, Petit I, Porozov S, Goichberg P, Avigdor A, Sagiv S, Nagler A, Naparstek E, Lapidot T. 2005 Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. Blood 106, 2120-2127. (doi:10.1182/blood-2004-12-4969)
59. Loeffler H, Rastetter J, Haferlach T. 2000 Blood and Bone Marrow. In Atlas of Clinical Hematology (eds H Loeffler, J Rastetter, T Haferlach), pp. 27-291. Heidelberg, Germany: Springer.
60. Berger DP, Engelhardt R, Henss H. 2008 Basic principles of chemotherapy. In Concise manual of hematology and oncology (eds DP Berger, R Engelhardt, H Henss, R Mertelsmann), pp. 65-68. New York, NY: Springer.
61. Meyer JA et al. 2013 Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45, 290-294. (doi:10.1038/ng.2558)
62. Dy GK, Adjei AA. 2006 Principles of chemotherapy. In Oncology - an evidence-based approach (eds AE Chang, DF Hayes, HI Pass, RM Stone, PA Ganz, TJ Kinsella, JH Schiller, VJ Strecher), pp. 14-40. Heidelberg, Germany: Springer.
63. Chessells JM. 1998 Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br. J. Haematol. 102, 423-428. (doi:10.1046/j.1365-2141. 1998.00776.x)
64. Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL. 2012 Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 119, 5201-5210. (doi:10.1182/blood-2012-01-401687)
65. Saito Y et al. 2010 Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28, 275-280.
66. Löwenberg B et al. 2003 Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl. J. Med. 349, 743-752. (doi:10.1056/NEJMoa025406)
67. Liesveld JL, Lichtman MA. 2010 Acute Myelogenous Leukemia. In Williams Hematology (eds K Kaushansky, M Lichtman, E Beutler, T Kipps, J Prchal, U Seligsohn), pp. 1277-1330. New York, NY: McGraw Hill.
68. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T. 2009 Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114, 2220-2231. (doi:10.1182/blood-2009-03-213389)
69. Thiede C et al. 2002 Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99, 4326-4335. (doi:10.1182/blood.V99.12.4326)
70. Weisser M, Kern W, Schoch C, Hiddemann W, Haferlach T, Schnittger S. 2005 Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 90, 881-889. (Pubitemid 41024890)
71. Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. 1987 The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 69, 1771-1776. (Pubitemid 17091639)
72. Tavor S et al. 2008 The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 22, 2151-2158. (doi:10.1038/leu.2008.238)
73. Irvine AE, Magill MK, Somerville LE, McMullin MF. 1998 Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia. Exp. Hematol. 26, 435-439. (Pubitemid 28198742)
74. Yamauchi T et al. 2013 A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 33, 3947-3951.
75. Crooks GM. 2010 Lymphopoiesis. In Williams hematology (eds K Kaushansky, M Lichtman, E Beutler, T Kipps, J Prchal, U Seligsohn), pp. 1095-103. New York. NY: McGraw Hill.
76. Neumeister B, Besenthal I, Boehm BO. 2009 Klinikleitfaden Labordiagnostik. Munich, Germany: Elsevier.
77. Harrison WJ. 1962 The total cellularity of the bone marrow in man. J. Clin. Pathol. 15, 254-259. (doi:10.1136/jcp.15.3.254)
78. Cartwright GE, Athens JW, Wintrobe MM. 1964 The kinetics of granulopoiesis in normal man. Blood 24, 780-803.
79. Klaus J et al. 2007 Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur. J. Haematol. 78, 21-28. (doi:10.1111/j.0902-4441.2006.t01-1-EJH2895.x)
80. Malinowska I, Stelmaszczyk-Emmel A, Wasik M, Rokicka-Milewska R. 2002 Apoptosis and pH of blasts in acute childhood leukemia. Med. Sci. Monit. 8, CR441-CR447. (Pubitemid 34694654)
81. Savitskiy VP, Shman TV, Potapnev MP. 2003 Comparative measurement of spontaneous apoptosis in pediatric acute leukemia by different techniques. Cytometry B Clin. Cytom. 56, 16-22. (doi:10.1002/cyto.b.10056)
82. Buxton ILO, Benet LZ. 2011 Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism and elimination. In Goodman and Gilman's the pharmacological basis of therapeutics (eds LL Brunton, BA Chabner, BC Knollman), pp. 17-41. New York, NY: McGraw Hill.
83. Werner B, Dingli D, Traulsen A. 2013 A deterministic model for the occurrence and dynamics of multiple mutations in hierarchically organised tissues. J. R. Soc. Interface 10, 20130349. (doi:10.1098/rsif.2013.0349)
84. Ross SM. 1996 Stochastic processes. New York, NY: Wiley.
85. Ross SM. 2006 Simulation. London, UK: Elsevier.
86. Klein RW, Roberts SD. 1984 A time-varying Poisson arrival process generator. Simulation 43, 193-195. (doi:10.1177/003754978404300406)